Emergent BioSolutions Inc (NYSE:EBS) Sees Significant Increase in Short Interest theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
PRINCETON, N.J., Nov. 13, 2023 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an.
Drugmaker Indivior Plc clinched a US contract worth up to $111 million for its opioid antidote part of the government’s preparation for a potential bioterrorism attack with drugs such as fentanyl that can be released into the air. The contract will secure US supplies of Opvee, an opioid reversal medication that…
Operator: Good afternoon, everyone. I am the operator for today’s call. Thank you for joining today as Emergent discusses the Operational and Financial Results for the Third Quarter of 2023.
Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of $M and Adjusted EBITDA of $20MUpdates FY 2023 guidance GAITHERSBURG, Md., Nov. 08,.